Part of the criticism of the one reported case of human preimplantation genome editing (PGE) turned on the inadequacy of the purpose for which it was undertaken (inherent immunity to HIV) and its target (the CCR5 gene). The discussion of CCR5 in this context reveals the different values that inform the idea of acceptable uses of PGE and of the conditions of responsible biomedical innovation among the scientist responsible and his critics. While the use of PGE for any indication remains unacceptable (or, at the very least, premature), neither position offers a satisfactory response to this prospective biotechnology.
Portland Press would like to thank Dr Silvia Camporesi (Kings College London) for her input into the initial discussions around some of the concepts covered in this issue of Emerging Topics in Life Sciences, and for securing some of the contributors and content.
Search for other works by this author on:
Perspective| November 14 2019
Preimplantation genome editing: CCR5 in China
- Views Icon Views
- Share Icon Share
- Cite Icon Cite
Pete Mills; Preimplantation genome editing: CCR5 in China. Emerg Top Life Sci 27 November 2019; 3 (6): 695–700. doi: https://doi.org/10.1042/ETLS20190114
Download citation file: